10 Nov 2021 --- Chr. Hansen and Lonza’s joint venture Bacthera and microbiome therapeutics company Seres Therapeutics are teaming up to manufacture SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI). SER-109 consists of purified Firmicutes spores, based on their modulatory role in the life cycle of C. difficile and disease pathogenesis. Lonza highlights SER-109 has the potential to be the “first-ever” live biotherapeutic product (LBP) to be produced commercially.
